Literature DB >> 17390744

Successful use of cinacalcet HCl in a patient with end-stage renal failure and refractory secondary hyperparathyroidism due to parathyromatosis.

R Unbehaun1, W Lauerwald.   

Abstract

We present the case of a 65-year-old male on long-term dialysis for end-stage renal failure, who developed persistent secondary hyperparathyroidism after subtotal parathyroidectomy, which proved refractory to treatment. Parathyromatosis, a rare cause of recurrent hyperparathyroidism, which may develop when tissue seeded into the neck during subtotal or total parathyroidectomy becomes hyperfunctioning [Maxwell and Winearls 1997], was diagnosed. The patient had excessively high levels of circulating parathyroid hormone (PTH), elevated serum calcium and deteriorating cardiovascular status. Repeated surgery and treatment with high-dose vitamin D failed to provide a sustained decrease in serum PTH levels. Administration of cinacalcet HCl, a second generation calcimimetic, at doses of 30 - 180 mg/day provided a gradual and sustained suppression of PTH (> 1,700 - 344 ng/l) without increasing the calcium-phosphate product.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390744     DOI: 10.5414/cnp67188

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

1.  Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.

Authors:  Masahiro Yamamoto; Hiroaki Ogata; Masahide Mizobuchi; Noriyo Yoshida; Chiaki Kumata-Maeta; Fumihiko Koiwa; Kanji Shishido; Eriko Kinugasa
Journal:  Clin Exp Nephrol       Date:  2011-10-20       Impact factor: 2.801

2.  Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl.

Authors:  Rieko Eriguchi; Junko Umakoshi; Yoshihiro Tominaga; Yuzuru Sato
Journal:  NDT Plus       Date:  2008-05-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.